SG11202109623WA - Combinations of anti-ildr2 antibodies and pd-1 antagonists - Google Patents

Combinations of anti-ildr2 antibodies and pd-1 antagonists

Info

Publication number
SG11202109623WA
SG11202109623WA SG11202109623WA SG11202109623WA SG 11202109623W A SG11202109623W A SG 11202109623WA SG 11202109623W A SG11202109623W A SG 11202109623WA SG 11202109623W A SG11202109623W A SG 11202109623WA
Authority
SG
Singapore
Prior art keywords
antagonists
combinations
ildr2
antibodies
ildr2 antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
Lars Röse
Uwe Gritzan
Spencer Liang
Andrew Pow
John Hunter
Ofer Levy
Ilan Vaknin
Original Assignee
Bayer Ag
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Compugen Ltd filed Critical Bayer Ag
Publication of SG11202109623WA publication Critical patent/SG11202109623WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG11202109623W 2019-04-11 2020-04-06 Combinations of anti-ildr2 antibodies and pd-1 antagonists SG11202109623WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832320P 2019-04-11 2019-04-11
PCT/EP2020/059745 WO2020207961A1 (en) 2019-04-11 2020-04-06 Combinations of anti-ildr2 antibodies and pd-1 antagonists

Publications (1)

Publication Number Publication Date
SG11202109623WA true SG11202109623WA (en) 2021-10-28

Family

ID=70224379

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109623W SG11202109623WA (en) 2019-04-11 2020-04-06 Combinations of anti-ildr2 antibodies and pd-1 antagonists

Country Status (15)

Country Link
US (1) US20220169736A1 (es)
EP (1) EP3952910A1 (es)
JP (1) JP2022528472A (es)
KR (1) KR20210151808A (es)
CN (1) CN113645999A (es)
AR (1) AR118621A1 (es)
AU (1) AU2020271352A1 (es)
BR (1) BR112021020148A2 (es)
CA (1) CA3136510A1 (es)
IL (1) IL287093A (es)
MX (1) MX2021012406A (es)
PE (1) PE20212271A1 (es)
SG (1) SG11202109623WA (es)
TW (1) TW202104275A (es)
WO (1) WO2020207961A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
PL2769729T3 (pl) 2007-09-04 2019-09-30 Compugen Ltd. Polipeptydy i polinukleotydy i ich zastosowanie jako cel dla leków do wytwarzania leków i środków biologicznych
BR112014018481A2 (pt) * 2012-02-01 2017-07-04 Compugen Ltd anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
CA3083675A1 (en) * 2017-11-30 2019-06-06 Bayer Aktiengesellschaft Ildr2 antagonists and combinations thereof

Also Published As

Publication number Publication date
US20220169736A1 (en) 2022-06-02
CA3136510A1 (en) 2020-10-15
AU2020271352A8 (en) 2022-04-07
WO2020207961A1 (en) 2020-10-15
EP3952910A1 (en) 2022-02-16
KR20210151808A (ko) 2021-12-14
TW202104275A (zh) 2021-02-01
JP2022528472A (ja) 2022-06-10
CN113645999A (zh) 2021-11-12
MX2021012406A (es) 2022-01-19
IL287093A (en) 2021-12-01
AR118621A1 (es) 2021-10-20
AU2020271352A1 (en) 2021-10-07
BR112021020148A2 (pt) 2021-12-21
PE20212271A1 (es) 2021-11-30

Similar Documents

Publication Publication Date Title
IL276731A (en) Antibodies against CD73 and methods of using them
IL276340A (en) PD-1 agonistic antibodies and their uses
IL280963A (en) Anti-5gdf1 antibodies, compounds and methods of use
ZA202000051B (en) Antibodies that specifically bind pd-1 and methods of use
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
ZA202006737B (en) Anti-sirpa antibodies and methods of use thereof
IL270214A (en) Anti-sortilin antibodies and methods of using them
IL287282A (en) Anti-mertk antibodies and methods of using them
IL290741A (en) Antibodies against cd-96 and methods of using them
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
IL277212A (en) Anti-KLK5 antibodies and methods of use
IL279648A (en) Anti-SIRP-in-cell 1 antibodies and methods of using them
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
IL285401A (en) Anti-clec2d antibodies and methods of using them
IL282424A (en) ALK2 antibodies and methods of using them
IL283884A (en) Antibodies against il-36 and methods of using them
IL280338A (en) Anti-SIGLEC-5 antibodies and methods of using them
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
PL3430054T3 (pl) Sposoby leczenia nowotworów z zastosowaniem antagonistów wiązania z osią PD-1 i przeciwciał anty-GPC3
EP3676294A4 (en) ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF
EP4061848A4 (en) ANTI-ROR-2 ANTIBODIES AND METHODS OF USE
SG11202113221RA (en) Anti-cd137l antibodies and methods of using same
IL279227A (en) Anti-SIGLEC-7 antibodies and methods of using them
IL273538A (en) Anti-TRKB Monoclonal Antibodies and Methods of Use
IL288886A (en) Antibodies and methods of use